MarketPeel
Insider Trading Intelligence
TK

Tara Lynn Kieffer

ENTA
SR. VP, NEW PRODUCT DEV. · ENANTA PHARMACEUTICALS INC · CIK 0001834835
FILING MIX · LIFETIME55%/45%
BUYS
16
SELLS
13
TOTAL VALUE
$671.2K
COMPANIES
1
ACTIVE SINCE
Dec 2020
HOLDINGS NOW
37,182
AVG SELL PX
$21.40
TRADE KIND
SHOWING 29 / 29
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Tara Lynn Kieffer, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+33.33%-0.98%+0.20%-1.18%+1.46%
14d3+33.33%+3.65%+1.22%+2.43%+6.16%
30d3+33.33%+17.83%+1.73%+16.10%+24.38%
60d3+33.33%+7.90%+3.64%+4.26%-0.57%
90d3+66.67%+19.07%+5.08%+14.00%-5.25%
180d3+66.67%-12.30%+13.78%-23.43%-23.43%
1y3(1 pending)+100.00%-25.76%+22.75%-48.50%-48.50%
2y3(1 pending)+50.00%+24.39%+45.02%-20.62%-20.62%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ENTA · 37,182 shares · as of Feb 12, 2026
025,00050,00075,000100,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 16 buys / 13 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,57532,195Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Product Strategy Officer
3,257$14.25$46.4K33,925Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
4,98737,182Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Product Strategy Officer
2,106$14.23$30.0K30,620Dec 5, 2025Dec 5, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Product Strategy Officer
753$14.12$10.6K32,726Dec 1, 2025Dec 3, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
100,000100,000Nov 25, 2025Nov 26, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Product Strategy Officer
3,326$5.59$18.6K33,479Feb 12, 2025Feb 14, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
7,50036,805Feb 12, 2025Feb 14, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
2,283$8.06$18.4K29,305Dec 6, 2024Dec 10, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Product Strategy Officer
753$8.60$6.5K31,588Dec 1, 2024Dec 3, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
81,00081,000Nov 27, 2024Nov 27, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
7,266$12.33$89.6K32,341Jun 17, 2024Jun 17, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
3,32040,580Feb 12, 2024Feb 14, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Product Strategy Officer
973$12.41$12.1K39,607Feb 12, 2024Feb 14, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, New Prod. Strat. & Dev
2,125$9.63$20.5K37,260Dec 5, 2023Dec 6, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, New Prod. Strat. & Dev
753$9.49$7.1K39,385Dec 1, 2023Dec 5, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
83,00083,000Nov 22, 2023Nov 22, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
9,25035,116Feb 13, 2023Feb 15, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
11,74746,863Feb 13, 2023Feb 15, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, New Product Dev.
6,725$52.77$354.9K40,138Feb 13, 2023Feb 15, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, New Product Dev.
498$44.33$22.1K25,866Dec 1, 2022Dec 5, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
18,50026,364Nov 23, 2022Nov 28, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
40,00040,000Nov 23, 2022Nov 28, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, New Product Dev.
552$62.49$34.5K7,864Feb 14, 2022Feb 15, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
3277,127Feb 14, 2022Feb 15, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,2898,416Feb 14, 2022Feb 15, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
28,40028,400Nov 19, 2021Nov 23, 2021View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
6,8006,800Nov 19, 2021Nov 23, 2021View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
65,00065,000Dec 7, 2020Dec 8, 2020View →
Other insiders · ENTA
Loading peer insiders…
About this filer
CIK 0001834835
ROLE
Sr. VP, New Product Dev.
PRIMARY
ENTA
COMPANIES
1
ACTIVE SINCE
Dec 2020
MARKETPEEL · /INSIDER/0001834835DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback